Trends and Hotspots in the Health Economics Evaluation of Chronic Fatigue Syndrome.
Wan, Hejia, Wei, Bingqi, Qian, Wenli et al. · Journal of multidisciplinary healthcare · 2024 · DOI
Quick Summary
This study looked at 180 research articles published between 1991 and 2024 to understand what scientists know about the costs and benefits of treating ME/CFS. The researchers found that very few studies have examined the economics of ME/CFS care, especially in China, and that cognitive-behavioral therapy is the most commonly studied treatment. They also noticed a possible link between ME/CFS and depression when looking at health economics data.
Why It Matters
This systematic overview reveals major gaps in health economics research for ME/CFS, a condition where treatment decisions are often hindered by insufficient cost-benefit data. Understanding where research is concentrated and where it is lacking helps patients, clinicians, and funders identify priorities for generating evidence that could improve access to effective, affordable care. The finding that CBT dominates the literature despite ongoing debates about its evidence base highlights the need for economic evaluations of other promising treatments.
Observed Findings
Very limited number of health economics evaluations of ME/CFS exist globally, with particularly sparse literature from China
Cost-effectiveness analysis is the dominant health economics methodology applied to ME/CFS
Cognitive-behavioral therapy is the most frequently studied intervention in ME/CFS health economics literature
Collaboration networks among institutions and authors in this field remain weak
Potential association between ME/CFS and depression appears in health economic literature
Inferred Conclusions
Health economics research on ME/CFS is severely underfunded and underrepresented compared to the disease burden
Current evidence base is heavily skewed toward CBT evaluation, potentially limiting exploration of other treatment options
Stronger institutional collaboration and international cooperation are needed to generate comprehensive economic evidence
Multiple treatment modalities require simultaneous health economic evaluation to inform equitable, cost-effective care pathways
Remaining Questions
Why is health economics research on ME/CFS so scarce compared to other chronic conditions, and what barriers prevent funding and publication?
What This Study Does Not Prove
This is a map of published literature, not a clinical trial or outcome study; it cannot prove that any treatment is effective or cost-effective for ME/CFS. The study does not evaluate the quality or validity of the articles it analyzed, so it does not determine whether existing economic conclusions are accurate. Correlation between depression and ME/CFS in economic literature does not establish causation or whether depression is primary, secondary, or coincidental.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
How do the economic findings on CBT compare to economic data for other treatments (e.g., pacing, exercise rehabilitation, emerging pharmacotherapies)?
What explains the potential association between ME/CFS and depression in health economic contexts—is it comorbidity, diagnostic overlap, or artifact of study design?
How could health economics research be scaled up in underrepresented regions like China to reflect global ME/CFS burden?